Geopolitical Risks and Pharmaceutical Supply Chains: Building Resilience Amid Tariffs and Trade Wars
Modern global politics and economic uncertainty are reshaping pharmaceutical supply chains. Trade wars, tariffs, and geopolitical tensions have disrupted the flow of Active Pharmaceutical Ingredients (APIs), raw materials, and finished products. For therapeutic goods manufacturers, these challenges demand proactive strategies to maintain compliance, ensure continuity, and protect patient safety. Whilst international policy may be out of your control, there are action you can take to understand the current geopolitical landscape, its impact on pharma supply chains, and practical steps for building manufacturing resilience in your business.
Current Geopolitical Landscape
The global pharmaceutical sector is navigating an era of heightened geopolitical volatility.
- US–China Trade Tensions: The US has announced tariffs of up to 100% on branded drugs imported from countries without domestic manufacturing facilities, directly impacting global supply chains and prompting major pharmaceutical companies to invest in US-based production. The UK, meanwhile, has secured a zero-tariff agreement for pharmaceuticals, ensuring continued access to the US market.
- Sanctions and Export Controls: Sanctions on countries supplying critical raw materials, such as China and Russia, have disrupted access to active pharmaceutical ingredients (APIs) and key starting materials (KSMs).
- Regional Conflicts: Ongoing conflicts in Ukraine and the Middle East, as well as tensions in the Taiwan Strait, threaten logistics routes and the stability of supply chains.
In July 2025, the US announced new tariffs affecting over 150 countries, with pharmaceutical imports facing initial rates of 20–40%, potentially rising to 200% over time. Companies have a one-year grace period to relocate production to the US before the full tariff is applied.
The tariffs aim to boost domestic pharmaceutical manufacturing, reduce reliance on foreign suppliers, and lower the US trade deficit. This could lead to increased investment, job creation, and innovation in supply chain management. However, there are notable downsides: higher tariffs have raised production costs, resulting in increased drug prices and supply chain disruptions. These changes have exacerbated shortages of critical medicines and risked patient health outcomes.
Internationally, pharmaceutical exporters face reduced access to the US market, potential revenue losses, and retaliatory tariffs, further fragmenting global supply chains.
While the tariffs may strengthen US manufacturing and trade balance, they also introduce significant risks of higher costs, instability, and reduced access to essential medicines, with global repercussions.
- Rising Nationalism and Protectionism: Many countries are adopting protectionist policies, increasing tariffs, and introducing local content requirements, which create volatility in pricing, availability, and lead times for essential pharmaceutical components.
Impact on Pharma Supply Chains
Pharmaceutical supply chains are highly globalised, with APIs often sourced from India and China, excipients from Europe, and packaging materials from multiple regions. Geopolitical disruptions can lead to:
- Increased Costs: Tariffs and duties raise production costs, which may be passed on to consumers.
- Delays and Shortages: Customs delays and export restrictions can cause shortages of critical raw materials and finished products.
- Compliance Risks: Rapid supplier changes, without proper qualification, increase the risk of non-compliance with GMP standards.
- Strategic Shifts: Companies such as Johnson & Johnson, Celltrion, and CSL are investing billions in US-based manufacturing to mitigate tariff exposure and ensure supply continuity.
IChinese pharma firms like WuXi AppTec and WuXi Biologics have altered project plans, stockpiled supplies, and shifted testing locally to mitigate the impact of US–China trade tensions. (Reuters, 2025)
Regulatory Considerations
Regulators expect manufacturers to maintain product quality and patient safety regardless of external disruptions. Key expectations include:
- Supplier Qualification: Comprehensive audits and risk assessments for new suppliers.
- Change Control: Documented processes for managing supplier changes.
- Data Integrity: Ensuring electronic records remain secure during supply chain transitions.
- Business Continuity Planning: Demonstrating preparedness for regulatory inspections.
Failure to comply may result in warning letters, product recalls, or market access restrictions.
Risk Mitigation Strategies
To counter geopolitical risks, companies should adopt multi-layered strategies:
- Diversify Supplier Base: Establish secondary suppliers across different regions to avoid single-point failures.
- Implement Predictive Analytics: Use AI-driven tools to forecast demand and identify geopolitical hotspots.
- Strengthen Quality Agreements: Include clauses for emergency supply, GMP compliance, and contingency planning.
- Build Strategic Inventory Buffers: Maintain safety stocks for APIs and critical excipients, balancing cost and shelf-life.
- Relocate Manufacturing: Relocate manufacturing closer to key markets to reduce exposure to tariffs and logistics disruptions.
- Secure Political Risk Insurance: Protect against losses from sanctions or sudden policy changes.
- Enhance Digital Visibility: Deploy blockchain and Internet of Things (IoT) for real-time tracking and traceability.
- Scenario Planning: Regularly conduct stress tests and scenario analyses to prepare for sudden disruptions.
- Engage in Policy Advocacy: Collaborate with industry groups to influence trade policy and regulatory frameworks.
Technology and Digital Tools for Resilience
Digitalisation can enhance visibility and agility in supply chains:
- Blockchain for Traceability: Provides tamper-proof records of material movement.
- IoT Sensors: Enable real-time monitoring of shipment conditions.
- Cloud-Based QMS: Standardises documentation and compliance across global sites.
- AI-Driven Risk Analysis: Identifies potential disruptions and recommends mitigation actions.
A global vaccine manufacturer faced API shortages due to sudden export restrictions. By leveraging predictive analytics and diversifying suppliers, they maintained production continuity and avoided regulatory non-compliance. Their approach included rapid supplier qualification and integration of blockchain for transparent documentation.
PharmOut has several blogs considering the implementation and importance of AI and digitisation in the pharmaceutical industry, including a review of the recent regulatory draft updates, to help manufacturers understand their options and compliance requirements in this space:
- Pharma 4.0 Principles: Driving Digital Transformation in GMP Manufacturing
- Digital Twins in Pharma 4.0
- Draft Publication GMP Annex 22 Artificial Intelligence
- Annex 11 Draft Update: Transforming Computerised Systems in GMP Environments
Outlook
Geopolitical risks are unlikely to disappear. Manufacturers should expect continued volatility driven by trade disputes, climate-related disruptions, and regional conflicts. Building resilience requires a combination of strategic planning, technological investment, and cultural adaptation toward proactive risk management.
PharmOut Services
PharmOut can help manufacturers navigate geopolitical challenges through:
- Supply chain risk assessments and contingency planning.
- Supplier qualification and GMP compliance audits.
- Implementation of digital tools for traceability and risk management.
Explore our GMP training courses at onlinegmptraining.com for practical insights, or contact us via the website or via email for assistance.
Frequently Asked Questions (FAQ)
They can lead to API shortages, increased costs, compliance challenges, and delays in product delivery.
Diversifying suppliers, predictive analytics, nearshoring, strategic inventory buffers, and scenario planning.
Tariffs can significantly raise production costs, which may translate into higher consumer prices unless mitigated by onshoring or trade agreements.
Blockchain, IoT, and AI enhance visibility, traceability, and predictive risk management.
Through supply chain risk assessments, GMP audits, and implementation of digital compliance tools.
Yes, regulators expect documented contingency plans and robust supplier qualification processes.
